What is the prevalence of Congenital Nephrotic Syndrome Finnish Type?

Congenital Nephrotic Syndrome Finnish Type (CNF) is an ultra-rare genetic disorder with an estimated birth incidence of approximately 1 in 8,200 live births in Finland. Outside of the Finnish population, the condition is significantly rarer, often occurring as isolated, sporadic cases worldwide.

What is the global prevalence and incidence of Congenital Nephrotic Syndrome Finnish Type?

Congenital Nephrotic Syndrome Finnish Type is categorized as an ultra-rare disease. In Finland, where the condition was first described, the incidence is well-documented at 1 in 8,200 births due to a founder effect. Globally, the prevalence is much lower and difficult to quantify precisely, as most cases outside of Finland are identified only through genetic testing of families with a history of the disorder. Because the condition presents with severe symptoms immediately after birth, it is rarely overlooked, but underdiagnosis can occur in regions with limited access to molecular genetic screening.

Does Congenital Nephrotic Syndrome Finnish Type affect genders and ages differently?

Congenital Nephrotic Syndrome Finnish Type affects males and females with equal frequency, as it follows an autosomal recessive inheritance pattern. Regarding age of onset, this is strictly a pediatric condition. Symptoms typically begin in utero or within the first three months of life. The following list highlights key epidemiological characteristics of the disease:

• Onset: Almost exclusively presents in the neonatal period (within 0-3 months of life).


• Inheritance: Autosomal recessive (both parents must carry the NPHS1 gene mutation).


• Global Status: Ultra-rare outside of the Finnish population.


• Community Data: Currently, 4 individuals are sharing their lived experiences with Congenital Nephrotic Syndrome Finnish Type on DiseaseMaps.org, providing a vital real-world perspective on this rare diagnosis.

Why is accurate data for Congenital Nephrotic Syndrome Finnish Type challenging to collect?

Accurate prevalence data for Congenital Nephrotic Syndrome Finnish Type is challenging to maintain because many affected infants may be misdiagnosed with other forms of nephrotic syndrome before genetic confirmation. Additionally, the clinical severity often leads to high mortality in regions without access to intensive neonatal care and early renal transplantation, which can skew survival statistics and prevalence counts. Global registries are essential for better understanding the true burden of Congenital Nephrotic Syndrome Finnish Type.

Next steps

• Consult a pediatric nephrologist or geneticist for definitive molecular testing of the NPHS1 gene.


• Connect with the DiseaseMaps.org community to share experiences with other families managing Congenital Nephrotic Syndrome Finnish Type.


• Reach out to rare disease advocacy groups to stay informed about clinical trials and emerging research for nephrotic syndromes.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: Congenital nephrotic syndrome of Finnish type (ORPHA:654).


• NIH GARD: Genetic and Rare Diseases Information Center - Congenital nephrotic syndrome, Finnish type.


• OMIM: Nephrotic syndrome, congenital, 1; NPHS1 (Entry #256300).


• PubMed: "Congenital nephrotic syndrome: a review of the Finnish type" (Clinical literature database).